相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
A. du Bois et al.
ANNALS OF ONCOLOGY (2010)
Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
Peter M. Ellis et al.
CLINICAL CANCER RESEARCH (2010)
BIBF 1120 for the treatment of non-small cell lung cancer
Martin Reck
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Cediranib (recentin, AZD2171) reverses ABCB1-and ABCC1-mediated multidrug resistance by inhibition of their transport function
Li-yang Tao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2
Chun-ling Dai et al.
CANCER LETTERS (2009)
Photodynamic therapy inhibits p-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a
Patrick Ming-Kuen Tang et al.
MOLECULAR CANCER (2009)
Vandetanib (Zactima, ZD6474) Antagonizes ABCC1-and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function
Li-sheng Zheng et al.
PLOS ONE (2009)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
Chun-ling Dai et al.
CANCER RESEARCH (2008)
Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol
Veronique Gagnon et al.
APOPTOSIS (2008)
Erlotinib (Tarceva, OSI-774) antagonizes ATP-bInding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance
Zhi Shi et al.
CANCER RESEARCH (2007)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity
L. Zahiragic et al.
LEUKEMIA (2007)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
Alessandro Morabito et al.
ONCOLOGIST (2006)
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
FJ Giles et al.
LEUKEMIA RESEARCH (2006)
ERK activation by Thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance
Su-Young Oh et al.
EXPERIMENTAL CELL RESEARCH (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Characterization of a side population of cancer cells from human gastrointestinal system
Naotsugu Haraguchi et al.
STEM CELLS (2006)
Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo
Z Shi et al.
CANCER BIOLOGY & THERAPY (2006)
Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment
Ricardo Perez-Tomas
CURRENT MEDICINAL CHEMISTRY (2006)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells
T Kitazaki et al.
LUNG CANCER (2005)
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal
Cheol-Hee Choi
CANCER CELL INTERNATIONAL (2005)
Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance
LW Fu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein
H Minderman et al.
CLINICAL CANCER RESEARCH (2004)
Predicting drug sensitivity and resistance:: Profiling ABC transporter genes in cancer cells
G Szakács et al.
CANCER CELL (2004)
Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318
LM Chen et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1
R Tang et al.
LEUKEMIA (2004)
Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract
P Limtrakul et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity
RW Robey et al.
BRITISH JOURNAL OF CANCER (2003)
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
LA Doyle et al.
ONCOGENE (2003)
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
C Knuefermann et al.
ONCOGENE (2003)
The role of ABC transporters in clinical practice
GD Leonard et al.
ONCOLOGIST (2003)
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
KA West et al.
DRUG RESISTANCE UPDATES (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
The human ATP-binding cassette (ABC) transporter superfamily
M Dean et al.
GENOME RESEARCH (2001)
Multidrug resistance (MDR) in cancer - Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
R Krishna et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2000)
分享论文
